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Abstract. Pharmacogenomics studies the involvement of interindivid-
ual variations of DNA sequence in different drug responses (especially
adverse drug reactions). Knowledge Discovery in Databases (KDD) pro-
cess is a means for discovering new pharmacogenomic knowledge in bio-
logical databases. However data complexity makes it necessary to guide
the KDD process by representation of domain knowledge. Three domains
at least are in concern: genotype, drug and phenotype. The approach de-
scribed here aims at reusing whenever possible existing domain knowl-
edge in order to build a modular formal representation of domain knowl-
edge in pharmacogenomics. The resulting ontology is called SO-Pharm
for Suggested Ontology for Pharmacogenomics. Various situations en-
countered during the construction process are analyzed and discussed. A
preliminary validation is provided by representing with SO-Pharm con-
cepts some well-known examples of pharmacogenomic knowledge.
1 Introduction
Pharmacogenomics is the study of genetic determinants of drug responses. It
involves relationships between at least three actors of interindividual differences
in drug responses: genotype, drug, and phenotype (Fig. 1)[1]. Relevant genotype
features are mostly genomic variations and particularly Single Nucleotide Poly-
morphisms (SNP). The latters are one-nucleotide substitutions occurring in a
studied population with a minimum frequency of 1 %. Such genomic variations
modulate drug effect, and have consequences on individual phenotype from the
microscopic level (gene expression, protein activity, molecule transport, etc.) to
the macroscopic level (clinical outcomes, etc.).
At present, best-recognized and completely developed examples of genomic
variations altering drug response in human are monogenic traits acting on drug
metabolism. Nevertheless, description of complex polygenic systems has recently
proven that regulatory networks and many non genetic factors (e.g., environ-
ment, life style) also influence the effect of medications. Consequently, the dis-
covery of new pharmacogenomic knowledge is a challenging task that necessitates
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Fig. 1. Triangular schematization of the pharmacogenomic domain.
the management of complex data. For example, the design of a clinical trial in
pharmacogenomics relies on the selection of genes involved in drug response,
selection of associated relevant genomic variations and on knowledge about the
phenotypes associated with these genomic variations [2]. An interesting research
direction is the integration of biological data stored in public annotated biological
data banks, and clinical data resulting from clinical trials. This integration may
allow, in a second stage, the discovery of pharmacogenomic knowledge thanks
to the KDD process.
The KDD process is aimed at extracting from large databases information
units that can be interpreted as reusable knowledge units (such as RDF/OWL
triples). This process is based on three major steps: (a) the datasets are extracted
from selected data sources and prepared for data mining, (b) are mined (with
symbolic or numerical methods), finally, (c) the extracted information units are
interpreted by domain expert to become reusable knowledge units [3]. All along
this process, domain knowledge, embedded within an ontology, can be used to
guide the various steps:
a) During the preparation step it facilitates integration of heterogeneous data.
b) During the mining step, domain knowledge guides the filtering of input and
output data.
c) In the interpretation step, it helps the experts for reasoning on the extracted
units.
In order to achieve KDD in pharmacogenomics, we decided to develop a
knowledge-based approach and therefore to explicit domain knowledge within an
ontology. More and more biomedical ontologies are being developed today and
often cover overlapping fields. To favor reuse of and access to ontologies, most
biological ontologies are freely available. For instance, the Protégé ontologies li-
brary [4] provides various formal ontologies and the Open Biomedical Ontologies
(OBO) portal [5] gathers many controlled vocabularies for the biomedical do-
main. Although the associated ontology is not available, the PharmGKB project
has led to the construction of a valuable structured repository for pharmacoge-
nomic data, aimed at catalyzing scientific research in this domain [6]. It provides
a data model and a partial vocabulary for genotype and phenotype data of in-
dividuals involved in pharmacogenomic studies. In previous work, we developed
the SNP-Ontology as a formal representation of genomic variation domain [7].
This paper describes the construction process of a “Suggested Ontology
for pharmacogenomics”(SO-Pharm), that reuses existing ontologies designed for
pharmacogenomics sub-domains: genotype, drug, and phenotype. Section 2 de-
scribes the method used to build SO-Pharm and its content. Section 3 presents
a preliminary testing of the ontology thanks to assertions of some established
pharmacogenomic knowledge. Section 4 concludes on the work.
2 SO-Pharm Construction
2.1 Methodology Choice
Semiautomatic methods such as classification, itemset search, association rule
extraction, text mining can be employed for ontology construction [8]. However,
a manual construction is preferred here because of the objectives assigned to the
ontology. In addition, the complexity of the field has favored a close collaboration
with domain experts, nicely compatible with manual construction. Indeed, one
difficulty consists in choosing and defining adequate concepts and properties for
expressing pharmacogenomic knowledge. Manual construction is associated here
with the use of a clearly defined methodology. Outlines of iterative processes
for ontology construction have been described in [9,10,11]. We adapt here these
methodologies to the case of pharmacogenomics, based on four steps:
(i) specification, embedding definition of ontology domain and scope;
(ii) conceptualization, that includes definition of list of terms and of concepts,
and their articulation with existing ontologies;
(iii) formalization, i.e., the translation of the conceptualization in a knowledge
representation formalism (e.g. description logics);
(iv) implementation, i.e., coding the formalized ontology in a knowledge repre-
sentation language (e.g. OWL).
In the next sections we analyze and discuss the original orientations adopted
during the SO-Pharm construction process.
2.2 Construction Issues
Specification. Domain and scope of SO-Pharm are primarily defined as follows.
The domain considered should cover pharmacogenomic clinical trials. The ontol-
ogy has to precisely represent individuals and groups of individuals involved in
trials, their genotype, their treatment, their observed phenotype and the poten-
tial pharmacogenomic relations discovered between these concepts. Currently,
SO-Pharm concepts do not cover epigenotype features, regulatory networks or
metabolic pathways. SO-Pharm scope is to guide KDD in pharmacogenomics.
According to the various steps of KDD process, SO-Pharm should reveal helpful
in the following situations:
– integrating complementary data from various scopes: e.g. protein annota-
tions and enzyme activity measurement;
– reconciling heterogeneous data: e.g. heterogeneous descriptions of genomic
variations pertaining from locus specific databases and dbSNP;
– guiding data mining: for instance selection of a given class of genomic vari-
ations according to relations between these variations and the focus of the
study;
– expressing data mining results as knowledge units: in order to compare with
existing knowledge units and to infer new knowledge units;
– reusing of discovered pharmacogenomic knowledge: e.g. knowledge sharing
between several independant projects.
During the specification step some strict nomenclature guidelines (e.g., for
naming classes, associations, concepts, properties) are defined for the whole con-
struction process. Then lists of domain terms are established. In the case of SO-
Pharm ontology, the domain expert constitutes four primary term lists thanks
to his own knowledge regarding respectively clinical trial, genotype, treatment,
and phenotype descriptions. In parallel, data or knowledge resources in the do-
main are listed. These highly heterogeneous resources, including conceptual data
model (in UML or UML-like), XML schemas, databases, ontologies, controlled
vocabularies are displayed in Table 1 (n.b.: * are OBO ontologies). The study of
their structure and content allows to considerably enrich the term lists.
The previous resource list is then refined for selecting relevant reusable knowl-
edge resources according to following criteria (Table 2). First, it has been decided
to take into account OBO ontologies, which are mostly used and known. Second,
we have preferred the ontologies involved in the OBO-Foundry project that tries
to adopt quality principles in ontology development [12]. The current resource
list may be extended in the future and enriched with other interesting resources
such as GO, Pathway Ontology, NCI, eVOC, Amino Acid Ontology, GandrKB.
Conceptualization. A UML class diagram is used here for representing the
conceptual model of SO-Pharm. Term lists are exploited to identify ontology
concepts which are assigned a name and a precise definition (free text). In SO-
Pharm, a clinical item (or clinical data, or item) is defined as the measurment of
a quantity for a given person, during a particular event, according to a measur-
ment method. As well, a drug is composed of chemical compounds and may be
included in a drug treatment and may have a commercial name. When concepts
are identified, their hierarchical and non-hierarchical (i.e. object properties) re-
lations are modeled by UML class diagrams. These diagrams are well adapted
for conceptualization of domain knowledge because of their expressiveness and
openness [13]. Fig. 2, 3 and 4 display UML class diagrams designed during SO-
Pharm construction.
Articulation between the SO-Pharm concepts and external ontologies con-
cepts is also established during this step (see Table 2 for prefix legend in UML
class diagrams). The kind of relation (i.e. embedding or extension) invoked for
reusing an ontology depends on its type [10]. Indeed, the majority of ontologies
in biomedical domain may be organized into three categories: meta-ontologies
providing domain-independent concepts and properties to be used as compounds
for more specific ontologies (e.g. DOLCE, SUMO); domain reference ontologies
representing a particular domain of reality and sorting entities of the domain
Table 1. List of explored resources for constructing term lists of the various domains
Resourcename Resource type Domain URL
dbSNP XML schema, data
model
genotype http://www.ncbi.nlm.nih.gov/projects/S-
NP/
HapMap XML schema genotype http://www.hapmap.org/
HGVBase DTD, data model genotype http://hgvbase.cgb.ki.se/
OMIM Data resource genotype,
phenotype
http://www.ncbi.nlm.nih.gov/omim/
OMG SNP Data model genotype http://www.omg.org/technology/docume-
nts/formal/snp.htm
MECV Controlled vocabulary genotype http://www.ebi.ac.uk/mutations/
PharmGKB XML schema, data
model
genotype,
drug,
phenotype
http://www.pharmgkb.org/
Pharmacogenetics
Ontology
Controlled vocabulary genotype,
phenotype
http://www.pharmgkb.org/home/project-
s/project-po.jsp
Sequence Ontol-
ogy
Controlled vocabulary* genotype http://song.sourceforge.net/
Gene Ontology Controlled vocabulary* genotype http://www.geneontology.org/
PubChem Data resource drug http://pubchem.ncbi.nlm.nih.gov/
RX-Norm Controlled vocabulary drug http://www.nlm.nih.gov/research/umls/-
rxnorm/index.html
CDISC XML schema phenotype http://www.cdisc.org/
ICD-10 Controlled vocabulary phenotype http://www.who.int/classifications/icd/
Disease Ontology Controlled vocabulary* phenotype http://diseaseontology.sourceforge.net
Mammalian Phe-
notype
Controlled vocabulary* phenotype http://www.informatics.jax.org/searches-
/MP form.shtml
PATO Controlled vocabulary* phenotype http://obo.sourceforge.net/
ChEBI Controlled vocabulary* drug http://www.ebi.ac.uk/chebi/
Pathway Ontol-
ogy
Controlled vocabulary* genotype,
phenotype
http://rgd.mcw.edu/tools/ontology
SNOMED-
Clinical
Controlled vocabulary phenotype http://www.snomed.org/snomedct/gloss-
ary.html
Table 2. List of selected resources for constructing SO-Pharm
Ontology name Description Prefix Namespace
MECV genomic variation classification MECV http://www.loria.fr/˜coulet/onto-
logy/mecv.owl
SNP-Ontology genomic variations SNPO ˜/ontology/snpontology.owl
Pharmacogenetics
Ontology
describes genotyping and pheno-
typing methods
PO ˜/ontology/pharmacogeneticsont-
ology.owl
Disease Ontology a classification of disease DO ˜/ontology/diseaseontology.owl
Mammalian Pheno-
type
phenotype features MPO ˜/ontology/mammalianphenotyp-
eontology.owl
PATO attributes and values for pheno-
type description
PATO ˜/ontology/pato.owl
ChEBI molecular compounds CHEBI ˜/ontology/chebi.owl
Clinical item
Genotype item
Smoking behavior
SNPO::Variant
Phentoype item
PATO::Value PATO::UnitPATO::QuantityPATO::Attribute
MPO::Mammalian phenotype
MECV::SO::Chromosome variation
MECV::Genomic variation
Life style
Genomic variation
Epigenotype item Endophenotype item
Disease diagnostic
DO::Diseases and injuries
Chromosomic variation
Behavior item
Alcohol behavior
Feed behaviour
Drug behaviour
Genomic genotype
Observed allele
SNPO::Sequence
Heterozygote genotype
Homozygote genotype
Treatement
1 2
Fig. 2. UML class diagram for clinical item.
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Fig. 3. UML class diagram for clinical trial.
CHEBI::CHEBI_23367
CHEBI::CHEBI_23888
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Fig. 4. UML class diagram for clinical trial protocol.
according to constraints expressed in a formal language (e.g. description logics);
and terminology-based application ontologies which are controlled vocabularies
often designed to annotate biological databases [14]. Most of OBO ontologies
belong to this third family -except for the PATO ontology that can be consid-
ered as a meta-ontology. In SO-Pharm, several highly specialized vocabularies
such as Disease Ontology are embedded meaning that these ontologies are reused
in an ontology having a wider scope. On the opposite, formal ontologies, such
as SNP-Ontology, are high level domain representations extending definitions of
more specific concepts pertaining from other ontologies. For example, the variant
concept of SNP-Ontology subsumes (i.e. extends the definition of) the genomic
variation concept in SO-Pharm. The latter itself subsumes other more specific
concepts from the OBO Sequence Ontology (e.g. single deletion).
In summary, SO-Pharm construction involves the design of modules favoring
the reuse of concept definitions existing in other ontologies. Besides these reused
concepts, additional SO-Pharm concepts and properties are defined locally.
Formalization and Implementation. SO-Pharm is implemented with the
Protégé knowledge editor and coded in OWL. Formalization and implementation
steps are nested. On the basis of previously designed UML class diagrams, con-
cepts and (object and datatype) properties are formally defined in the Protégé
framework. For example:
(1) clinical item v ∃ measuredOn.individual
u ∃ measuredDuring.clinical trial event
u ∃ measuredAccording.measurement method
(2) drug v ∀ isComposedOf.chemical compound
u ∃ isPartOf.drug treatment
u ∃ isCommercialisedAs.substance
Unfortunately, no system allows an automatic conversion of UML class di-
agrams into OWL statements. Simple classes and associations are easily con-
verted, but complex ones need particular attention. For example, since the de-
scription logic formalism on which OWL is based is limited to binary relation-
ships, the translation of UML n-ary relationships is not straightforward. The
most common way to represent n-ary relationships in an ontology formalism
is reification [15]. In our work, conceptualization prevents n-ary relationships
by preferring addition of new classes or association classes with several binary
relationships.
Apart from SNP-Ontology, ChEBI and Disease Ontology which have been
directly downloaded in OWL (http://www.fruitfly.org/˜cjm/obo-download/),
most external ontologies are not available in OWL. They had to be translated
first. Pharmacogenetics Ontology has been manually coded in OWL from text
sources. Because of redundancies, Mutation Event Controlled Vocabulary and
Sequence Ontology have been manually integrated and implemented in OWL.
PATO and Mammalian Phenotype Ontology have been converted from OBO
format to OWL thanks to the BONG-Protégé plugin [16]. OWL-translated on-
tologies are then associated to namespaces and are prefixed (Table 2) for being
virtually imported in SO-Pharm where they are articulated by concepts defini-
tions:
(3) CHEBI : molecular entities v chemical compound
(4) MECV : genomic variation v genomic variation v SNPO : variant
The consistency and the class hierarchy of SO-Pharm including reused ontologies
have been validated with Racer 1.9 at each stage of the implementation thanks to
standard reasoning mechanisms [17]. Manual construction and expert contribu-
tion appear as solid advantages for articulating existing ontologies in a sensible
way. It allows a proper use of reasoning mechanisms despite of unclear/various
purpose concepts that co-exist or overlap in ontologies.
3 Preliminary Testing of SO-Pharm semantics
As a preliminary validation of the ontology, several examples of published phar-
macogenomic knowledge have been expressed with the SO-Pharm concepts.
This is performed by asserting individual cases presenting genotype, treatment
and phenotype features described in the litterature. The assertions of individ-
uals and related information (clinical trial, treatment) lead us to refine SO-
Pharm concepts. Genotype (encompassing several genomic variation), homozy-
gosity/heterozygosity, poor/rich metabolizer, anamnesis, treatment effect are ex-
amples of concepts added during the first round of testing in order to be able to
handle the representation of selected precise pharmacogenomic examples. Groups
of individuals have been artificially constituted to gather individuals presenting
common traits. Three groups of individuals are presented in expression (5), (6)
and (7):
(5) demyelinised patient v person
u ∀ presentsGenotype. ( ∃isTheGenotypeObservedFor.(3 {rs1142345})
u ∃isComposedOf. 3 {G})
u ∀ presentsPhenotype. ( ∀measuredAccording.(3 {6TGN proto})
u ∀PATO : hasAttribute.(3 {6TGN conc})
u ∀PATO : hasV alue.(3 {high}))
u ∀ isEnrolledIn. ( ∀isDefinedBy.(∀isComposedOf.
(3 {mercaptopurine treatment}))
The meaning of (5) is that demyelinised patients are persons who present both
the allele G for the genomic variation rs1142345, a high concentration in 6-TGN
and are treated with mercaptopurine in a clinical trial.
(6) over anti coagul patient v person
u ∀ presentsGenotype. ( ∀isTheGenotypeObservedFor.(3 {rs1057910})
u ∀isComposedOf.(3 {C}))
u ∀ isComposedOf. ( 3 {CY P2C9 2})
u ∀ presentsPhenotype. ( ∀measuredAccording.(3 {bleeding obs})
( ∀PATO : hasAttribute.(3 {bleeding})
u ∀PATO : hasV alue.(3 {high bleeding}))
u ∀ isEnrolledIn. ( ∀isDefinedBy.(∀isComposedOf.
(3 {warfarin treatment}))
Patients with an over anti-coagulation (6) are persons who present both the allele
C for the genomic variation rs1057910, the CYP2C9*2 genotype, and important
bleeding and are treated with warfarin in a clinical trial.
(7) venous thrombos patient v person
u ∀ isComposedOf. ( ∀sex.(3 {female}))
u ∀ presentsClinicalData. ( ∀measuredAccording.(3 {drug anamnesis})
u ∀isComposedOf.(3 {oral contraceptive}))
u ∀ isComposedOf. (3 {F2 A20210}t 3 {F5 A1691})
The patient group with venous thrombosis (7) are women who are using oral
contraceptive and present the F2 A20210 or the F5 A1691 genotype. Additional
assertions have led to localize and fix a few mistakes in the ontology instantiation,
and to precise restrictions on object and datatype relationships. The number of
required modifications decreased with each new assertion until the quasi-stability
of the ontology was reached.
In view of expressing pharmacogenomic knowledge units, SO-Pharm was en-
riched with a simple property mayBeRelated that allows to link genotype item,
phenotype item and chemical compound. Every required modification in the
ontology is done according to a new construction iteration by updating the con-
ceptual model, looking for reusable concepts, and finally modifying the ontology.
SO-Pharm is a crucial component for a future knowledge-based application
dedicated to pharmacogenomic knowledge discovery. A complete validation has
now to be conducted in the frame of the intended knowledge-based application,
i.e. aimed at evaluating how SO-Pharm is able to guide the KDD process. A
significant issue will be to develop appropriate wrappers to achieve heterogenous
data integration as in [7].
SO-Pharm and external ontologies it includes are available (in OWL format)
at http://www.loria.fr/˜coulet/ontology/sopharm.owl. We plan to submit SO-
Pharm to OBO portal to gain in visibility and facilitate further improvements.
4 Conclusion
Much of the quality of the SO-Pharm ontology relies on the initial extensive enu-
meration of term lists and use cases (specification and conceptualization steps).
Expert interviews and overview of existing ontologies are necessary for that pur-
pose. Interestingly case studies aimed at expressing already existing knowledge
extracted from the litterature lead us to enrich SO-Pharm with additional con-
cepts in an iterative process.
Embedding and extension strategies are used to anchor existing ontologies to
SO-Pharm concepts. This conceptualization task will become more and more im-
portant since more and more autonomous ontologies are produced in the biomed-
ical domain, e.g. for representing phenotype with formal ontologies.
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